Lucid Diagnostics

Lucid Diagnostics is a manufacturer of equipment for the diagnosis of oncological diseases.. Founding date: 2018. Employees 12 people.

History

2021: Access to the Nasdaq Exchange

On October 14, 2021, Lucid Diagnostics entered the Nasdaq exchange. At the time of the start of trading, the company's quotation rate fell by 8.9% compared to the IPO price. Cantor and Canaccord Genuity act as joint securities offering managers, and BTIG and Needham act as co-lead placement managers.

As part of the listing, Lucid Diagnostics raised $70 million, selling 5 million shares during an IPO at a price of $14 apiece, which is at the bottom of the expected range of $14-16 per share.

Cancer diagnostic equipment manufacturer Lucid Diagnostics enters Nasdaq exchange

Lucid Diagnostics is developing solutions to diagnose and treat chronic heartburn, a disease that can cause esophageal cancer. Lucid Diagnostics has new commercial products, such as a EsoCheck tool for taking cell samples from the esophagus. The company also has its own BETRNet research network and a DNA test EsoGuard to detect biomarkers of pathogenic processes.

Lucid Diagnostics is a subsidiary of PAVmed and uses PAVmed specialists for development. PAVmed holds more than 70% stake in Lucid Diagnostics and will retain a controlling stake after the IPO. In its filing with the Securities and Exchange Commission, Lucid Diagnostics noted that the company disclaims any intention or obligation to publicly update or revise any forward-looking statements. However, Lucid Diagnostics is a product company that has intrigued many investors. The products of the company EsoCheck and EsoGuard allow you to collect cells in the esophagus without endoscopy. Given the movement of the system health care to reduce costs based on technology, the proposal of this company aroused optimism among many early investors.^[1]

Notes